Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959073 | 0.88 | HRH4 (0.44) | HRH4HRH3PDE2APDE3AKARS1 | |
| SCHEMBL1352123 | 0.86 | ADRB1 (0.57) | HRH4HRH3KARS1SYKDPP4 | |
| SCHEMBL5086363 | 0.86 | ADRB1 (0.57) | HRH4HRH3KARS1SYKDPP4 | |
| SCHEMBL1352121 | 0.86 | ADRB1 (0.57) | HRH4HRH3KARS1SYKDPP4 | |
| SCHEMBL20132972 | 0.84 | PDE2A (0.49) | HRH4HRH3PDE2APDE3ASYK | |
| SCHEMBL14349617 | 0.83 | PDE2A (0.48) | HRH3PDE2APDE3ADPP4DPP7 | |
| SCHEMBL1350907 | 0.81 | KARS1 (0.60) | HRH4HRH3KARS1SYKDPP4 | |
| SCHEMBL22755428 | 0.81 | ADRB1 (0.47) | HRH4HRH3PDE2APDE3AADRB1 | |
| SCHEMBL1350904 | 0.81 | KARS1 (0.60) | HRH4HRH3KARS1SYKDPP4 | |
| SCHEMBL25964570 | 0.80 | PDE2A (0.44) | HRH4HRH3PDE2APDE3ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | HRH4 3134/4885HRH3 3509/4885PDE2A 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.